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ABSTRACT
Prostacyclin is a powerful cardioprotective hormone released by the endothelium of all blood vessels.
Prostacyclin exists in equilibrium with other vasoactive hormones and a disturbance in the balance
of these factors leads to cardiovascular disease including pulmonary arterial hypertension. Since it’s
discovery in the 1970s concerted efforts have been made to make the best therapeutic utility of
prostacyclin, particularly in the treatment of pulmonary arterial hypertension. This has centred on
working out the detailed pharmacology of prostacyclin and then synthesising new molecules based on
its structure that are more stable or more easily tolerated. In addition, newer molecules have been
developed that are not analogues of prostacyclin but that target the receptors that prostacyclin
activates. Prostacyclin and related drugs have without doubt revolutionised the treatment and
management of pulmonary arterial hypertension but are seriously limited by side effects within the
systemic circulation. With the dawn of nanomedicine and targeted drug or stem cell delivery systems it
will, in the very near future, be possible to make new formulations of prostacyclin that can evade the
systemic circulation allowing for safe delivery to the pulmonary vessels. In this way, the full therapeutic
potential of prostacyclin can be realised opening the possibility that pulmonary arterial hypertension
will become, if not curable, a chronic manageable disease that is no longer fatal. This review discusses
these and other issues relating to prostacyclin and its use in pulmonary arterial hypertension.
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DISCOVERY
Prostacyclin is very important cardio protective lipid mediator released by blood vessels. It is one
member of the eicosanoid family of mediators, which also include prostaglandins, thromboxanes and
leukotrienes. Prostacyclin was discovered in 1976 by a group led by Salvador Moncada and John Vane.1
Initially called prostaglandin (PG)X, prostacyclin was identified as an unknown lipid mediator formed
by microsomes prepared from rabbit or pig aortas that inhibited human platelet aggregation and
relaxed some preparations of isolated blood vessels. Early studies showed that PGX is the major
metabolite of arachidonic acid in the arterial walls of a number of species, including man.2
PGX was later identified as 5z-5,6-didehydro-9-deoxy-6,9a-epoxyprostaglandin F1 and renamed
as prostacyclin.3 Early studies attributed prostacyclin release as the mechanism mediating the
anti-thrombotic properties of the endothelium4 and its place as a fundamental mediator in
cardiovascular health was set. A current (2014) PubMed search of the term ‘prostacyclin’ generates
17958 hits with 1992 hits for the terms ‘prostacyclin’ and ‘pulmonary hypertension’. Pulmonary
hypertension is a devastating, progressive and ultimately fatal condition with few treatment options,
which, at best slow progression but do not cure the disease. Traditionally drugs have been designed to
target the pulmonary vasculature as either vasodilators or inhibitors of smooth muscle remodeling.
Most recently the right heart, which fails under the burden of extra work exerted on it by increased
pulmonary pressures, has become a viable therapeutic target in the search for new drugs to treat
pulmonary hypertension.
This review will cover what is known about the synthetic and receptor pathways associated with
prostacyclin and how this knowledge has been applied and translated to produce treatments.
Specifically the review will discuss how the known actions of prostacyclin provide a compelling case for
its utility for treatment of both pulmonary vessels and the right heart. The review will also identify the
limitations of prostacyclin therapies and speculate upon how modern medical technologies might be
applied to improve its utility in this disease. Finally, with the idea that pulmonary arterial hypertension
may, in the future, be treated with stem cell therapies to supplement organ regeneration and/or
transplant, the potential role of prostacyclin in these approaches will be highlighted.
SYNTHESIS OF PROSTACYCLIN
Endothelial cells are the predominant source of prostacyclin in the body and prostacyclin is the main
eicosanoid made by endothelial cells. As described below and illustrated in Figure 1 there are three key
steps to the synthesis of prostacyclin. Prostacyclin is synthesised from the 20 carbon fatty acid (20:4)
arachidonic acid by the concerted actions of cyclo-oxygeanse (COX) and prostacyclin synthase5
(Figure 1). The first step involves liberation of arachidonic acid from stores. Arachidonic acid is not
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Figure 1. Synthesis of prostacyclin. Prostacyclin (PGI2) is synthesized from arachidonic acid (AA) by the
concerted actions of the enzymes cyclo-oxygenase (COX) and prostacyclin synthase. AA is liberated by from
plasma phospholipids by phospholipase enzymes where it is metabolized to prostaglandin (PG)H2 by COX. PGH2
is then further metabolized by prostacyclin synthase to PGI2, by PGE2 synthases/isomerases to PGE2 or
thromboxane synthase to thromboxane (TXA2).
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normally free in cells but acetylated in membrane phospholipids. The best-studied pathway for
arachidonic acid liberation involves phospholipase A2 (Figure 1). There are multiple forms of
phospholipase A2 but cytosolic forms (cPLA2) and, in some circumstances, calcium-independent PLA2
(iPLA2) are thought to drive arachidonic acid liberation in endothelial cells. Arachidonic acid can also be
liberated through a secondpathway after phospholipase C cleaves an inositol triphosphate group, giving
diacylglycerol (DAG), which can then be hydrolyzed by lipases to monoacylglycerol and then to free
arachidonic acid and glycerol.
Once free inside the cell arachidonic acid is metabolized by various enzymatic and non-enzymatic
routes to eicosanoids (or icosanoids; lipid mediators derived from 20 carbon fatty acids). The second
step in prostacyclin formation is metabolism of arachidonic acid by COX in two stages. In the first stage
arachidonic acid is converted to prostaglandin (PG)G2 via an oxygenase reaction and then in the
second stage, to PGH2 by a peroxidase reaction. The third and final stage in prostacyclin synthesis is
the metabolism of PGH2 by prostacyclin synthase, which is one of a number of synthase enzymes
downstream of COX (Figure 1). It is the relative expression of these PG synthase enzymes that critically
dictate the profile of prostanoids released by a given cell type under different conditions. For example,
endothelial cells and platelets both express the isoform COX-1 but prostacyclin synthase is highly
expressed in endothelial cells with little or no thromboxane synthase. In contrast, in platelets
thromboxane synthase is highly expressed whilst there are negligible levels of prostacyclin synthase.
As a result, despite both tissue types being high expressers of COX-1, the prostanoid products they
produce are highly polarized and, in this way, perform diametrically opposed functions within the
cardiovascular system. Like COX, prostacyclin synthase is a P450 enzyme, expression of which in
endothelial cells, is regulated by shear stress and growth factors.
Pulmonary arterial hypertension is classically associated with reduced vasodilators (including
prostacyclin) and increased vasoconstrictors, which is why current therapies rely so heavily on
manipulation of vasoactive pathways. Specifically, in terms of eicosanoids, pulmonary arterial
hypertension is associated with reduced urinary markers of prostacyclin and increased markers of
thromboxane.6 This is in line with reduced prostacyclin synthase in lungs of patients with pulmonary
arterial hypertension.7 Further, transgenic mice overexpressing prostacyclin synthase or mice
inoculated with prostacyclin synthase gene8,9 are protected from development of disease symptoms.10
Prostacyclin synthase gene delivery in the form of genetically modified stem cells has also been
reported to protect against development of experimental pulmonary arterial hypertension.11,12
Once formed by endothelial cells prostacyclin doesn’t simply diffuse out of cells but is exported by
highly regulated transporter systems, most likely of the ATP-binding cassette transporters (ABC)13 class
with the likely member of this class most used for prostanoids, including prostacyclin, being multidrug
resistance protein 4 (MRP4/ABCC4).14 Once released from cells prostacyclin is then free to act on
receptors to mediate its actions. The idea that pulmonary arterial hypertension may be associated with
reduced secretion of prostacyclin at the level of a transporter has not been addressed and, where
tested, inhibition of MRCP4 leads to protection in animal models attributed to an action on
cGMP/cGMP transport.15 Nevertheless, the lack of literature in this area suggests that elucidation of
precise mechanisms of prostacyclin flux in pulmonary vessels during disease may provide insight and
new drug targets.
RECEPTOR PATHWAYS UTILIZED BY PROSTACYCLIN AND IMPLICATIONS FOR TREATMENTS IN
PULMONARY ARTERIAL HYPERTENSION
Once released by blood vessels prostacyclin produces its powerful protective effects on the vasculature
and platelets by activating cell surface receptors and in some tissues by activation of cytosolic
peroxisome proliferator-activated receptors (PPAR). For prostacyclin, the favored cell surface receptor is
known as the ‘IP’ receptor (Figure 2). IP receptors are members of the large and diverse group of
receptors known as G protein–coupled receptors (GPCRs). In the case of prostacyclin, IP receptors are
coupled to activation of the enzyme adenylate cyclase which converts ATP to the powerful second
messenger cAMP (Figure 2). The biological effects of cAMP in a given tissue, which are diverse, are
mediated by activation of cAMP-dependent protein kinases (also known as protein kinase A) and
Exchange protein activated by cAMP (Epac; Figure 2). In vascular smooth muscle cAMP mediates
relaxation and reduces proliferation and in platelets reduces thrombosis via regulation of calcium
levels and associated pathways. Protein kinase A and Epac act synergistically to inhibit vascular
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smooth muscle cell proliferation16 and whilst pulmonary artery smooth muscle cells express both of
these pathways, preliminary studies suggest that Epac is down regulated in pulmonary hypertension.17
As with other prostanoids, the complicating pharmacological feature of prostacyclin is that, whilst its
acts preferentially on its designated subtype (i.e. IP) receptors, it can cross over and activate any of the
other prostanoid receptors in particular circumstances (Figure 2). This means that, for example, where
IP receptors are limiting, prostacyclin can activate thromboxane (TP) receptors. As mentioned above,
the opposing properties of thromboxane and prostacyclin in the cardiovascular system are critical to
the maintenance of vascular health. This balance is broken when thromboxane is produced in excess,
or, similarly where IP receptors are saturated. In these settings prostacyclin becomes a mimetic for
thromboxane inducing vasoconstriction. Prostacyclin and related drugs can also cross over onto
constrictor EP and FP receptors, which, as with TP, can limit the dilator actions of prostacyclin, as well
as dilator EP and DP receptors which may have a beneficial effect. This issue of specificity is of
relevance to the use of prostacyclin drugs to treat pulmonary arterial hypertension since there is, as
with all pharmaceutical preparations, the danger of overriding local sensing pathways.
The existence of multiple IP receptor subtypes has been suggested in some tissues but these
observations are based on pharmacological studies and have not been validated at the gene level.
Nonetheless, the authors of a recent study claim to have conclusively identified two IP receptor
subtypes using a human airway epithelial cell line exposed to a host of IP agonists in the presence or
absence of a selective IP antagonist.18 Whilst this observation is potentially very important, it remains
to be seen whether the distinct IP receptor subtypes can be identified in other human cells.
The potential for GPCRs to homo- and hetero-dimerize is well established. IP receptors can form
homodimers via the interactions of disulphide bonds.19 Importantly IP receptors may also form
heterodimerize with thromboxane TP receptors (20). The IP-TPa complex has been suggested to have a
protective role in promoting a “PGI2-like” response from TPa activation by TP ligands.
20 After activation,
IP receptors are desensitized by PKC-dependent phosphorylation21 and receptor internalization,22
TP, FP, EP1, EP3
Prostacyclin (PGI2) EP2, EP4, DP
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Figure 2. Signaling pathways utilized by prostacyclin (PGI2). PGI2 acts preferentially on cell surface IP receptors
that activate adenylate cyclase to convert ATP to cAMP. cAMP activates protein kinase A and Exchange protein
activated by cAMP (Epac). In blood vessels and platelets this results in calcium sequestration and inhibition of
activation equating to vessel relaxation, reduced remodeling and reduced thrombosis respectively. These
signaling events also reduce inflammation. In the cytosol, PGI2 activates PPARb receptors which work by three
discreet pathways. Firstly, PPARb binds to RXR to drive transcription of target genes. Secondly it represses BCL6
and thirdly, when activated it can bind and repress PKCa. Activation of PPARb can lead to similar functional
effects to activation of IP receptors, although by these very different pathways. When PGI2 is present in excess
and these pathways are overwhelmed it can activate other prostanoid receptors leading to IP-type signaling in
the case of EP2, EP4 and DP or to functionally opposing effects in the case of TP, FP, EP1 or EP3 receptors.
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which constitute endogenous pathways to regulate and limit prostacyclin signalling. As is common for
drugs acting on natural receptor pathways the prospect of IP desensitization/internalization may be a
confounding factor in utilizing prostacyclin analogues as therapeutic interventions and, as discussed
can shunt biological responses away from dilator to constrictor pathways. Evidence of desensitisation
of IP receptors and/or their down stream pathways has been noted in clinical studies. In line with this
continuously infused epoprostenol is associated with tolerance in patients with severe pulmonary
hypertension, and dose adjustments have to be made to maintain clinical effects.23,24 Indeed, in
patients with pulmonary arterial hypertension secondary to COPD the dilator effects of epoprostenol on
pulmonary pressures were subject to tachyphylaxis within 24 hours.25
Prostacyclin can also work by activating the cytosolic nuclear receptor PPARb26 (Figure 2). PPARb is
considered to be anti-inflammatory in a number of settings where it acts by genomic and non-genomic
mechanisms26 (Figure 2). Importantly for the treatment of pulmonary arterial hypertension, the
prostacyclin drug, treprostinil, activates PPARb in platelets,27 lung fibroblasts28 and blood vessels.29
Work from our group and others has also shown that selective, non-IP, PPARb agonists relax
pulmonary artery smooth muscle cells30 and prevent hypertension in an hypoxic rat model.29 In animal
models we found that whilst the PPARb agonist GW0742 prevented pulmonary arterial hypertension,
reducing right heart hypertrophy, it did not reduce muscularization of vessels in the lung.29 This
suggested to us that PPARb agonists might have a protective action directly on the right heart in
pulmonary arterial hypertension. Recently we, with collaborators, tested this idea using a pulmonary
artery banding model where workload is applied to the right heart mechanically without any
contribution from pulmonary pressure per se.31 Of direct relevance, others have shown that PPARb
activation in adult hearts facilitates mitochondrial function and improves cardiac performance under
pressure-overload conditions.32 In our study, GW0742 prevented right heart remodeling and
transcripomic profiling of heart tissue suggested that the mechanism was classically genomic involving
the PPAR target gene Angptl4.31 Angptl4 is a member of the angiopoietin-like family and regulates
angiogenesis and lipid metabolism. While no data currently exist relating Angptl4 to idiopathic
pulmonary arterial hypertension, it has recently been associated with high-altitude adaptation in
Tibet33 and Angptl4 is associated with left heart failure where it protects against myocardial infarction
and no reflow through preservation of vascular integrity.34 These observations support the idea that
Angptl4 may be a viable mechanism by which PPARb activation leads to cardioprotection and suggest
that this pathway may be therapeutically important in other forms of heart failure, such as seen in
pulmonary arterial hypertension. This is an interesting notion since our work shows this is independent
of actions on vessels which means that activation of PPARb could be a good adjunct therapy to current
drugs acting on vasodilator pathways. In our work we have suggested that the time could be right for a
clinical study to assess the effects of PPARb in pulmonary arterial hypertension, since there are orally
active drugs available that have already been used man.35 However, this needs to be treated with
extreme caution for two key reasons. Firstly, PPARb drugs may negatively interact with current drugs29
and secondly PPARb drugs are associated with increased risk of cancer36,37 and warnings have been
issued for their use, particularly directed at sports performance dosing where illicit procurement of drug
maybe considered by athletes.
ROLE OF COX-1 AND COX-2 IN PROSTACYCLIN GENERATION AND IMPLICATIONS FOR
PULMONARY ARTERIAL HYPERTENSION
As described above, prostacyclin is formed from PGH2 produced by the enzyme COX. COX has two
isoforms COX-1, which is constitutively expressed and COX-2 that is induced at the site of
inflammation.38 COX-1 is the predominate enzyme present in endothelial cells and its loss in vessels
virtually abolishes release of prostacyclin.39–41 This is also true in conditions of inflammation
associated with atherosclerosis.42
However, COX-2 takes over from COX-1 as the driver for prostacyclin release under conditions of
gross systemic inflammation such as that associated with sepsis.43 Outside large vessels COX-2 is
expressed in some key tissues, including in the lung.40 It is now accepted that pulmonary arterial
hypertension is, at least in part, driven by inflammatory cytokines44–47 and interferon.48,49 With
this in mind our group was the first to suggest that induction of COX-2 by cytokines may be
implicated in pulmonary arterial hypertension.50 Others showed similar data in cells relevant to
pulmonary arterial hypertension.48,51–53 If prostacyclin is the main product of cells expressing COX-2
in the lungs in pulmonary arterial hypertension it is likely to form a protective responses. This idea
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is supported by data showing a detrimental effect of COX-2 gene deletion in mouse models of
pulmonary arterial hypertension.54,55 However, if prostacyclin synthase is overwhelmed and/or if the
IP receptor population is saturated, COX-2 will drive a constrictor response and this may explain a
protective effect of COX-2 inhibitors in other experimental models.56 It should be noted however, that
there is no evidence to suggest that this phenomenon predominates and the role of COX-2 and
associated prostacyclin release in human pulmonary arterial hypertension remains the subject of
investigation.
PROSTACYCLIN AS A DRUG TO TREAT PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is rare, but fatal, with mean survival rates without therapy of less than
2 years. The introduction of prostacyclin therapies in the early 1990s has led to increased survival rates
to around 5-7 years with some patients living with pulmonary arterial hypertension on prostacyclin
therapy for more than 10 years. The features of pulmonary arterial hypertension include reduced
prostacyclin/thromboxane balance, constriction, remodeling and thrombosis. With these features in
mind the therapeutic utility of prostacyclin (also known as epoprostenol) was assumed very early in the
field and in 1984 a placebo controlled trial was conducted where prostacyclin was continuously infused
in patients with peripheral vascular disease.57 This paved the way for a landmark trial in 1996 where
prostacyclin, was infused intravenously for 12 weeks in patients with pulmonary arterial hypertension.23
41 patients received prostacyclin and 40 the conventional treatment at the time, which consisted of
anticoagulants, oral vasodilators, diuretic agents, cardiac glycosides, and supplemental oxygen.
Exercise capacity, measured using the 6 minute walk test, was improved in all 41 patients treated with
prostacyclin but was reduced in the 40 patients treated with conventional therapy. Importantly,
mortality was improved in the patients administered prostacyclin. However, serious side effects were
noted in the prostacyclin arm, which included catheter associated sepsis. Epoprostenol (FLOLANw)
remains a therapeutic option in the treatment of pulmonary arterial hypertension but is seriously
limited by its very short half-life at room temperature and side effects associated with the need for
continuous infusion requiring permanent intravenous catheter and pump (Figure 3). To address some
of these limitations a number of more stable prostacyclin analogues have been developed for the
treatment of pulmonary arterial hypertension (Figure 4). These include iloprost (Ventavisw) and
treprostinil (Remodulinw), which together with epoprostenol constitute the current prostacyclin
therapies in patients with pulmonary arterial hypertension (Figure 3). Treprostinil, which has similar
pharmacodynamics to epoprostenol is more stable and can be administered subcutaneously and
intravenously. Iloprost is administered as an inhaled preparation using a nebulizer 6-9 times a day.
Treprostinil is also available in and inhaled formulation (TYVASOw; Figure 3) given approximately each
4 hours. A common and important feature of prostacyclin drug therapy is the need for slow, incremental
and individualized dosing where the patient is closely monitored for tolerability.
Prostacyclin drugs (with initial dosing ranges):
• Epoprostenol (FLOLAN®; IV infusion, 1-2ng/kg/min)
Activate IP> other PGRs
Activate PPAR receptors• Treprostinil (Remodulin®; IV infusion, 0.625-1.25ng/kg/min)
• iTreprostinil (TYVASO®; inhalation 4 times per day, 18mcg)
• oTreprostinil (Orenitram™; oral, 0.25mg, twice a day)
• Iloprost (Ventavis®, inhalation, 6-9 times per day, 2.5mcg)
Non-prostacyclin (IP) drugs:
• Selexipag (Uptravi®; oral; 200mcg twice a day)
Activates IP receptors
Non-prostacyclin (PPARβ) drugs
• GW0742 (not use clinically to treat PAH)
Activate PPARβ
Figure 3. Pulmonary arterial hypertension drugs acting on prostacyclin pathways. Synthetic prostacyclin
(epoprostenol), injected treprostinil, inhaled treprostinil (itreprostinil), oral treprostinil (otreprostinil) or iloprost
are drugs based on the structure of prostacyclin, which activate the IP receptor, but may also activate other
prostaglandin receptors (PGRs). Selexipag is a non-prostacyclin drug given orally which selectivity activates the
IP receptor. GW0742 is a non-prostanoid, non-IP small molecule drug that activates PPARb in experimental
models of pulmonary hypertension. Routes of administration and generally starting titration doses are shown.
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PROSTACYCLIN AND COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION
Despite their effectiveness and because of their limitations and side effects, prostacyclin drugs are
generally restricted to patients with pulmonary arterial hypertension and who are in functional class III
or IV.58 Intravenous epoprostenol is often the preferred drug with intravenous treprostinil given as an
alternative. Inhaled iloprost is generally reserved for patients for whom intravenous therapy is not
acceptable or appropriate. As prostacyclin drugs are reserved for patients with severe pulmonary
arterial hypertension in most cases they will be given in combination with either a phosphodiesterase
type 5 (PDE5) inhibitor and/or an endothelin receptor antagonist (ETRA).58 The utility and mechanism
of action of PDE5 inhibitors59,60 and ETRAs61 are reviewed in detail elsewhere. However, in brief, PDE5
inhibitors work by increasing the bioactivity of endogenously released NO. NO, like prostacyclin, is a
vasodilator, but acts on a parallel signaling pathway via activation of soluble guanylate cyclase leading
to increases in the second messenger cGMP. PDE5 removes cGMP, thus blocking PDE5 potentiates NO
signaling. The effects of NO and prostacyclin are additive in blood vessels60 and work in powerful
synergy in platelets.60,62 ETRA drugs, on the other hand, work independently of the NO or prostacyclin
pathways by blocking the actions of the powerful constrictor peptide endothelin-1. It is not clear how
the pharmacology of these three pathways affects particular combinations of drugs in pulmonary
arterial hypertension and there are no validated biomarkers that can predict which drugs will work
together optimally. However, this is an area of research that our group and others are investigating
using endothelial cells grown from blood progenitors allowing insights into vascular function in
patients with pulmonary arterial hypertension.63,64
LIMITATIONS OF PROSTACYCLIN DRUGS IN PULMONARY ARTERIAL HYPERTENSION
As with other treatments for pulmonary arterial hypertension prostacyclin drugs are very expensive with
estimated annual costs of $30,000 to more than $200,000 per patient per year in the United States.
However, the main limitations of prostacyclin drugs for those that require the drug to be infused are
infection and pain at the site of injection. In addition all forms of prostacyclin drugs are associated with
side effects such as systemic hypotension, flushing, jaw pain and nausea. Intense research efforts are
ongoing to address these limitations and include the development of small molecule, non-prostacyclin,
selective IP receptor agonists most notably selexipag (Figure 4). Selexipag is a potent, orally active a
pro-drug whose active metabolite, MRE269 (ACT-333679), is a selective prostacyclin IP receptor
agonist. Unlike prostacyclin analogue drugs, because selexipag is specific for the IP receptor, it has
little or no effect on other prostanoid receptors. This means that where drugs based on prostacyclin
structures may be limited by underlying constrictor actions on EP, TP or FP receptors, selexipag targets
(a) (b) (c) (d)
(e) (f ) (g) (h)
MRE269
• Selexipag• Iloprost
C22H32O4
• Treprostinil
C23H34O5
• Epoprostenol
C20H32O5 • C26H32N4O4S
• Mr 496.6
• MRE 269
•
• Mr 360.5
•
• Mr 390.5
•
• Mr 352.4
• C25H29N3O3
• Mr 419.5
Figure 4. 2D (a-d) and 3D (e-f) structures of prostacyclin drugs epoprostenol (a,e), remodulin (b,f) and iloprost
(c,g) and the non-prostacyclin IP agonist pro-drug selexipag (d,h). The active metabolite of selexipag is MRE269
where the terminal nitrogen is replaced with oxygen (see insert; panel d). Each of the listed drugs has similar
molecular weights.
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dilator IP pathways only. However, this high specificity for IP receptors means selexipag will also fail to
activate DP receptors and PPARb that may contribute to the efficacy of other prostacyclin drugs.
Nonetheless, a phase II proof of concept study showed favorable results65 and in 2009 the GRIPHON,66
(Prostacyclin (PGI2) Receptor agonist In Pulmonary arterial HypertensiON) trial was initiated by
Actelion to test the utility of selexipag in a randomized, multicenter, double-blind, placebo-controlled
trial in patients with pulmonary arterial hypertension. In June 2014 Actelion announced that initial
analysis of the GRIPHON study showed that selexipag decreased the risk of a morbidity/mortality and
that the overall tolerability profile of selexipag in GRIPHON was consistent with existing prostacyclin
therapies. According to the Actelion website67 in December 2014 marketing authorizations will be
submitted to the European Medicines Agency (EMA) for selexipag (Uptraviw) in the treatment of
pulmonary arterial hypertension with similar applications pending to the US Food and Drug
Administration (FDA). However, even if oral dosing with selexipag proves to be as efficacious as
prostacyclin drugs dosed by infusion or inhalation, it is still limited by side effects common to
prostacyclin therapy due to its actions on the systemic circulation. In the wake of success with orally
active IP-selective selexipag, most recently the FDA approved the first orally active formulation of a
prostacyclin drug, treprostinil (Orenitrame). Orenitrame is treprostinil in an extended-release tablet
formulation for the treatment of patients with pulmonary arterial hypertension.68 The approval comes
after the FREEDOM studies.69,70 Whilst current data in patients not previously taking prostacyclin drugs
are disappointing, studies show that in some patients oral treprostinil may successfully replace existing
use of continuously infused drug. However, as with selexipag, oral dosing does not prevent side effects
and future studies and development in formulations will be needed to improve prostacyclin drugs in all
their guises.
FUTURE OF PROSTACYCLIN DRUGS IN PULMONARY ARTERIAL HYPERTENSION
Clearly prostacyclin drugs in all their forms have proven utility in pulmonary arterial hypertension but
are severely limited by route of delivery and effects of on the systemic circulation. Attempts to
circumvent the need for drug infusion have been successful with drugs such as inhaled treprostinil and
iloprost and orally active selexipag, but the systemic side effects remain the limitation in realizing the
full potential of this class of drugs. One approach being adopted in other human diseases is
nanomedicine, where targeted drug delivery can improve efficacy and over come side effects (Figure 5).
The use of nanomedicine technology has, in some cases, revolutionized drug formulations for
treatment of cancer.71 Nanomedicine is a relatively young science and can be defined as the medical
application of nanotechnology, in the case of drug delivery systems this equates to the use of
formulations in the nanometer range. As the field grows the types of potential formulations suitable to
encapsulate drugs increases. The idea that this technology can be applied to drugs for pulmonary
arterial hypertension was recently reviewed72 but the idea remains relatively novel and untested.
Nevertheless, we suggest that the following approaches may solve the current limitations of
prostacyclin drugs. Firstly a safe and effective encapsulation of prostacyclin drug within a suitable
nanoparticle to evade the systemic circulation is required. This may be enough to allow specific
targeting of pulmonary vessels if similar characteristics of local tissue environment exist to those in
Figure 5. Targeted delivery of prostacyclin to affect pulmonary vessels in disease. Prostacyclin could be
encapsulated to form a nanomedicine formulation to protect it from metabolism and the systemic circulation.
Attachment of an antibody directed at a specific antigen within pulmonary arteries would allow for targeted
delivery and evasion of the systemic circulation.
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tumors. In tumors some nanomedcines can accumulate because of increased vascular leak and
reduced lymphatic drainage. However, in the case of specific delivery of a prostacyclin drug to affected
pulmonary vessels additional molecular engineering may be required. One approach to this would be
to use an antibody-drug conjugate (Figure 5). Here it would first be necessary to identify a specific
antigen expressed locally within pulmonary vessels, manufacture and humanize the antibody. This may
be possible by using comparative systems approaches such as proteomics, recently used to identify
translationally controlled tumor protein (TCTP) as a marker of pulmonary arterial hypertension.64 These,
of course, are not trivial tasks and would require the concerted efforts of chemists, bioengineers,
pharmacologists and clinicians.
FUTURE APPLICATION FOR THE PROSTACYCLIN PATHWAY IN STEM CELL AND ORGAN
REGENERATION THERAPIES
Current therapies have had dramatic effects at increasing the life expectancy of patients with
pulmonary arterial hypertension. However, ultimately, in most cases, these fail and in some patients
having a lung transplant is the only therapeutic option. Needless to say this is not a perfect solution nor
is it one that can benefit most patients. With this in mind there are increasing efforts in the use of stem
cell therapy to treat pulmonary arterial hypertension. This may be either at the level of giving stem cells
in an attempt to repopulate the diseased vessels in the pulmonary vasculature or, at the most
ambitious end of the spectrum, to grow lung tissue in bio incubators for transplant.
Prostacyclin pathways play a potentially important role in these approaches. Any stem cell therapy in
pulmonary arterial hypertension would require a fully functioning COX/prostacyclin synthase pathway
and would similarly require fully functioning prostacyclin receptors to be present. This type of approach
in stem cell and gene therapy has been reviewed elsewhere73y but remains very much at the theoretical
and experimental stage.
SUMMARY AND CONCLUSIONS
Prostacyclin is a multifaceted cardioprotective hormone released by the endothelium. Since its
discovery in the 1970s prostacyclin has been the subject of thousands of publications yet we are still
discovering new insights into its biology and pharmacology. Prostacyclin remains arguably the most
effective therapy for patients with pulmonary arterial hypertension but current drugs based on its
pharmacology have serious limitations. It is hoped that in the future specific targeting of prostacyclin
drugs alone, or in combinations with other medications can resolve these limitations and allow for less
frequent but more effective administration of high doses of drug, that will, if not cure this disease, at
least convert it to an effectively managed non-fatal condition.
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